Pfizer's dividend yield sits near 6%, but the company paid out more in dividends last year than it generated in free cash ...

Pfizer (NYSE:PFE) reported positive Phase 3 MagnetisMM-32 results for ELREXFIO in relapsed or refractory multiple myeloma.

Analysts on Wall Street project that Pfizer (PFE) will announce quarterly earnings of $0.72 per share in its forthcoming report, representing a decline of 17.2% year over year. Revenues are projected ...

Pfizer Inc. PFE on Tuesday released topline results from its Phase 3 MagnetisMM-32 study evaluating Elrexfio (elranatamab) as ...

Based on reported profit, Pfizer stock costs more than the market. At the October 27, 2026 close, it traded at 39.2 times its ...

Pfizer’s Elrexfio has taken another step on its path to potential commercial momentum: The drugmaker just announced another ...

In the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for ...

Pfizer’s Jeff Legos discusses how science, AI and patient insights are shaping cancer research and the next generation of ...

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before ...

About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks ...

Pfizer Inc. sees a path forward for an experimental lung cancer drug in combination with other medicines, despite it failing a key clinical trial.

Investigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20 ® on shared serotypes and for five ...